Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004864 · ClinicalTrials.gov registry record · Phase 1
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
A Phase 1 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004864: Completed Phase 1 study, sponsored by Montefiore Medical Center.
NCT00004864 is a Phase 1 study that has completed, run by Montefiore Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004864, a Phase 1 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as GEM 231 may inhibit the growth of cancer cells and make the tumor more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combining docetaxel and GEM 231 in treating patients who have recurrent or refractory solid tumors.
Interventions
- DRUG docetaxel
- DRUG GEM 231
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Est. Completion | 2000-06 |
| Phase | Phase 1 |
What the finished NCT00004864 record still lists
NCT00004864 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00004864 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004864 about?
NCT00004864 is a clinical study titled "Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as GEM 231 may inhibit the growth of cancer cells and make the tumor more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combini...
What is the current status of trial NCT00004864?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07. Estimated completion is 2000-06.
What interventions are being tested in trial NCT00004864?
The interventions under investigation include: docetaxel (DRUG), GEM 231 (DRUG).
Who is sponsoring clinical trial NCT00004864?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia